POLOXAMER 407-INDUCED CHRONIC HYPERLIPIDEMIA IS NOT ASSOCIATED WITH DISORDERS OF BLOOD GLUCOSE LEVELS
DOI:
https://doi.org/10.15547/tjs.2025.01.002Keywords:
Poloxamer 407, hyperlipidemia, glucose metabolism, diabetes type 2Abstract
PURPOSE: The aim of the study was to evaluate the effects of chronic poloxamer 407 treatment on some parameters of lipid and glucose metabolism in a rat experimental model and to test the potential of this treatment to induce a condition similar to diabetes type 2. METHODS: The following parameters of lipid and glucose metabolism were measured: blood concentration of total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, very low-density lipoprotein (VLDL) cholesterol, triglycerides and glucose concentrations following intravenous glucose tolerance test (IVGTT). Twelve male Wistar rats were used in the study. Rats were divided into two groups: 1) group C (control group) – rats from this group received no treatment during the entire experimental period; 2) group P (poloxamer group) – rats from this group were treated daily with poloxamer for a period of one month after which parameters of lipid and glucose metabolism were measured in both groups. RESULTS: Chronic poloxamer treatment induced significant changes in lipid metabolism parameters but did not affect glucose metabolism parameters. CONCLUSIONS: A 30 days experimental poloxamer treatment in rats is not associated with disorders of blood glucose levels.
References
. Ćirin, D., Krstonošić, V. and Poša, M., Properties of poloxamer 407 and polysorbate mixed micelles: Influence of polysorbate hydrophobic chain. Journal of industrial and engineering chemistry, 47: 194-201, 2017.
Dumortier, G., Grossiord, J. L., Agnely, F. and Chaumeil, J. C., A review of poloxamer 407 pharmaceutical and pharmacological characteristics. Pharmaceutical research, 23: 2709-2728, 2006.
Carvalho, G. C., Araujo, V. H. S., Fonseca-Santos, B., de Araújo, J. T. C., de Souza, M. P. C., Duarte, J. L. And Chorilli, M., Highlights in poloxamer-based drug delivery systems as strategy at local application for vaginal infections. International journal of pharmaceutics, 602, 120635, 2021.
Nugraha, D. H., Anggadiredja, K. and Rachmawati, H., Mini-review of poloxamer as a biocompatible polymer for advanced drug delivery. Brazilian Journal of Pharmaceutical Sciences, 58, e21125, 2022.
Gucu, A., Cavusoglu, I., Eris, C., Toktas, F., Goncu, T. and Ozyazicioglu, A., Effects of temporary vascular occluder poloxamer 407 Gel on the endothelium. Journal of Cardiothoracic Surgery, 8: 1-7, 2013.
Homan, K. A., Kolesky, D. B., Skylar-Scott, M. A., Herrmann, J., Obuobi, H., Moisan, A. and Lewis, J. A., Bioprinting of 3D convoluted renal proximal tubules on perfusable chips. Scientific reports, 6(1): 34845, 2016.
Batrakova, E. V. And Kabanov, A. V., Pluronic block copolymers: evolution of drug delivery concept from inert nanocarriers to biological response modifiers. Journal of controlled release, 130(2): 98-106, 2008.
Singh-Joy, S. D. and McLain, V. C., Safety assessment of poloxamers 101, 105, 108, 122, 123, 124, 181, 182, 183, 184, 185, 188, 212, 215, 217, 231, 234, 235, 237, 238, 282, 284, 288, 331, 333, 334, 335, 338, 401, 402, 403, and 407, poloxamer 105 benzoate, and poloxamer 182 dibenzoate as used in cosmetics. International journal of toxicology, 27: 93-128, 2008.
Palmer, W. K., Emeson, E. E. and Johnston, T. P., The poloxamer 407-induced hyperlipidemic atherogenic animal model. Medicine & Science in Sports & Exercise, 29(11): 1416-1421, 1997.
Peng, X., Lian, Z., Perrard, X.-Y. D., Xiao, Y., Ni, J., O’Brien, V., Dong, H., Pownall, H. J., Ballantyne, C. M. and Wu, H., Poloxamer 407 induces hypertriglyceridemia but decreases atherosclerosis in Ldlr−/− mice. Cells, 11(11): 1795, 2022.
Jayanti, N. E. and Said, R. M., A Review of Poloxamer 407-Induced Hyperlipidemia in In Vivo Studies. ITEGAM-JETIA, 10(50): 144-148, 2024.
Kumar, R., Akhtar, F. and Rizvi, S. I., Protective effect of hesperidin in Poloxamer-407 induced hyperlipidemic experimental rats. Biologia Futura, 72: 201-210, 2021.
Suárez-García, S., Caimari, A., Del Bas, J. M., Suárez, M. and Arola, L., Serum lysophospholipid levels are altered in dyslipidemic hamsters. Scientific Reports, 7(1): 10431, 2017.
Leon, C., Wasan, K. M., Sachs-Barrable, K. and Johnston, T. P., Acute P-407 administration to mice causes hypercholesterolemia by inducing cholesterolgenesis and down-regulating low-density lipoprotein receptor expression. Pharmaceutical research, 23: 1597-1607, 2006.
Bharti, S. K., Kumar, A., Prakash, O., Krishnan, S. and Gupta, A. K., Essential oil of Cymbopogon citratus against diabetes: Validation by in vivo experiments and computational studies. J Bioanal Biomed, 5(5): 194-203, 2013.
Bharti, S. K., Krishnan, S., Kumar, A., Rajak, K. K., Murari, K., Bharti, B. K. and Gupta, A. K., Antidiabetic activity and molecular docking of fructooligosaccharides produced by Aureobasidium pullulans in poloxamer-407-induced T2DM rats. Food chemistry, 136(2): 813-821, 2013.
Johnston, T. P. and Waxman, D. J., Circulating free fatty acids are increased independently of PPAR γ activity after administration of poloxamer 407 to mice. Canadian journal of physiology and pharmacology, 86(9): 643-649, 2008.
Korolenko, T., Johnston, T. P., Dubrovina, N. I., Kisarova, Y. A., Zhanaeva, S. Y., Cherkanova, M. S., ... and Zhukova, N. A., Effect of poloxamer 407 administration on the serum lipids profile, anxiety level and protease activity in the heart and liver of mice. Interdisciplinary toxicology, 6(1): 18-25, 2013.
Yin, N., Chu, T., Peng, Y., Yao, Y., Li, J., Xiang, B., ...and Yang, M., A novel rat model of fatty organ degeneration induced by poloxamer 407. Journal of Bio-X Research, 2(01): 41-45, 2019.
Naik, H. G., Maled, D. Y., Khanwelkar, C. C., Thorat, V. M., Jadhav, S. A. and Kolur, A., Effect of poloxamer 407 on the serum cholesterol and triglyceride of rabbits. Int J Med Pharm Sci, 4(02): 25-29, 2013.
Johnston, T. P. and Palmer, W. K., Mechanism of poloxamer 407-induced hypertriglyceridemia in the rat. Biochemical pharmacology, 46(6): 1037-1042,1993.
Johnston, T. P., The P-407–induced murine model of dose-controlled hyperlipidemia and atherosclerosis: a review of findings to date. Journal of cardiovascular pharmacology, 43(4): 595-606, 2004.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Trakia University
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
